Martin Tenniswood

miR Scientific LLC is an American healthcare company that specializes in the early and accurate detection, characterization, and monitoring of urological cancers. The private company has developed a proprietary, non-invasive platform called the miR Disease Management Platform®, which powers the miR Sentinel™ Prostate Cancer Test. This liquid biopsy urine test accurately detects, classifies, and monitors prostate cancer based on the interrogation of sncrnas extracted from non-dre urinary exosomes. The company is developing interoperable products and services to revolutionize the standards of care supporting urologic oncology. miR Scientific is a majority-owned operating subsidiary of Impact NRS LLC, headquartered in the United States with operating subsidiaries in Puerto Rico. The company was founded in 2014 by Rob Tenniswood, Martin Tenniswood, and Sam Salman. Sam Salman has been the CEO since 2014.

miR Scientific LLC is an American healthcare company that specializes in the early and accurate detection, characterization, and monitoring of urological cancers. The private company has developed a proprietary, non-invasive platform called the miR Disease Management Platform®, which powers the miR Sentinel™ Prostate Cancer Test. This liquid biopsy urine test accurately detects, classifies, and monitors prostate cancer based on the interrogation of sncrnas extracted from non-dre urinary exosomes. The company is developing interoperable products and services to revolutionize the standards of care supporting urologic oncology. miR Scientific is a majority-owned operating subsidiary of Impact NRS LLC, headquartered in the United States with operating subsidiaries in Puerto Rico. The company was founded in 2014 by Rob Tenniswood, Martin Tenniswood, and Sam Salman. Sam Salman has been the CEO since 2014.

miR Scientific LLC is an American healthcare company that specializes in the early and accurate detection, characterization, and monitoring of urological cancers. The private company has developed a proprietary, non-invasive platform called the miR Disease Management Platform®, which powers the miR Sentinel™ Prostate Cancer Test. This liquid biopsy urine test accurately detects, classifies, and monitors prostate cancer based on the interrogation of sncrnas extracted from non-dre urinary exosomes. The company is developing interoperable products and services to revolutionize the standards of care supporting urologic oncology. miR Scientific is a majority-owned operating subsidiary of Impact NRS LLC, headquartered in the United States with operating subsidiaries in Puerto Rico. The company was founded in 2014 by Rob Tenniswood, Martin Tenniswood, and Sam Salman. Sam Salman has been the CEO since 2014.

miR Scientific LLC is an American healthcare company that specializes in the early and accurate detection, characterization, and monitoring of urological cancers. The private company has developed a proprietary, non-invasive platform called the miR Disease Management Platform®, which powers the miR Sentinel™ Prostate Cancer Test. This liquid biopsy urine test accurately detects, classifies, and monitors prostate cancer based on the interrogation of sncrnas extracted from non-dre urinary exosomes. The company is developing interoperable products and services to revolutionize the standards of care supporting urologic oncology. miR Scientific is a majority-owned operating subsidiary of Impact NRS LLC, headquartered in the United States with operating subsidiaries in Puerto Rico. The company was founded in 2014 by Rob Tenniswood, Martin Tenniswood, and Sam Salman. Sam Salman has been the CEO since 2014.

miR Scientific LLC is an American healthcare company that specializes in the early and accurate detection, characterization, and monitoring of urological cancers. The private company has developed a proprietary, non-invasive platform called the miR Disease Management Platform®, which powers the miR Sentinel™ Prostate Cancer Test. This liquid biopsy urine test accurately detects, classifies, and monitors prostate cancer based on the interrogation of sncrnas extracted from non-dre urinary exosomes. The company is developing interoperable products and services to revolutionize the standards of care supporting urologic oncology. miR Scientific is a majority-owned operating subsidiary of Impact NRS LLC, headquartered in the United States with operating subsidiaries in Puerto Rico. The company was founded in 2014 by Rob Tenniswood, Martin Tenniswood, and Sam Salman. Sam Salman has been the CEO since 2014.